Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: David Lenigas answers investor questions in a detailed interview about UKOG, Doriemus, LGC Capital, AfriAg and Angus Energy.


Motif Bio Share Chat (MTFB)



Share Price: 41.25Bid: 41.25Ask: 41.75Change: 0.00 (0.00%)No Movement on Motif Bio
Spread: 0.50Spread as %: 1.21%Open: 40.75High: 41.75Low: 40.25Yesterday’s Close: 41.25


Share Discussion for Motif Bio


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


Ian.B
Posts: 14,220
Off Topic
Opinion:No Opinion
Price:41.25
View Thread (3)
RE: Paratek potential take over.
Sun 23:08
Hanibel clearly not a shareholder hes been talking this down for weeks. He apologised last week for spreading rumours then comes back with another pile of muddled garbage.
 
AllGuesswork
Posts: 143
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:41.25
RE: Paratek potential take over.
Sun 22:40
Hanibal. As others have suggested, you do seem to shy away from facts.

How about naming one of the fund managers you’ve been talking to?
Ivyspivey
Posts: 7,406
Off Topic
Opinion:No Opinion
Price:41.25
RE: Paratek potential take over.
Sun 22:22
Sorry Iclaprim better than Vancomycin-hard to do stuff in phone lol
Ivyspivey
Posts: 7,406
Off Topic
Opinion:No Opinion
Price:41.25
View Thread (3)
RE: Paratek potential take over.
Sun 22:21
Hannibal.You certainly come across as bearish unless you want a lower entry.
Yes GL has spoken to plenty of investors and there are funds invested as previously mentioned and are holding at least 35% (those holdings above 3%) there will be others below the 3% threshold.
Plus AMP and the MTFB concert party in total about 60% plus of the total so not sure what you mean by lack of institutional interest.Quite the reverse.
If you don£t understand why the Nasdaq listing is important then you need to research more.It is about the future.These are a US Company seeking to build into a billion dollar outfit.
There are nonFDA concerns over recent p3 results so where do you get that from.
Of course Iclaprim is novel and does not need to be better than Iclaprim only safer and within NI limits as you well know.
There are not concerns over getting a partner or needing to raise more money for HABP within MTFB only from folk who are looking for reasons to undermine the outstanding progress of Iclaprim when they can£t hoghlight any other issues.
hanibal
Posts: 160
Off Topic
Opinion:No Opinion
Price:41.25
RE: Paratek potential take over.
Sun 21:30
There are a lot more around. Graham did see many of them the last two years. Why was the Nasdaq listing so important and how did those investors welcome Motif?? Why is it still so difficult to get them on board?? Because we are so derisked and have such a bright future? We will all know in a few weeks. Would suggest till mid December, before everybody closes their books for 2017. Dont get ne wrong, I m not bearish, just wonder like many others here perhaps.
boomorbust
Posts: 9,209
Off Topic
Opinion:No Opinion
Price:41.25
hanibal
Sun 21:26
Have just been reading back over some of your posts and you mentioned that you have held other stocks when they announced phase III results. Can you advise which stocks they were and what market they were traded on?
Ian.B
Posts: 14,220
Off Topic
Opinion:No Opinion
Price:41.25
RE: Paratek potential take over.
Sun 21:12
Did you speak to invescos fund manager? Maybe sandgrove/ ,merreill Lynch (bank of america) fundmangers?
Over 30 % of the company held right there.
hanibal
Posts: 160
Off Topic
Opinion:Hold
Price:41.25
RE: Paratek potential take over.
Sun 20:40
Thats the feedback, I get from talking to some fundmanagers. I like Motif, but wonder as well, why the market treats the stock different.
UncommonSense
Posts: 170
Off Topic
Opinion:No Opinion
Price:41.25
RE: Paratek potential take over.
Sun 20:37
I think that the only big turn off to potential partners is the fact that it was knocked back once by the FDA. I don't think HABP has anything to do with it at all. You could understand why, since the report was pretty dire for Arpida at the time.

If you have never read it here is the link
https://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4394b3-01-FDA.pdf

It goes into great details about the issue with dosing, and pre-treatment, alongside the concerns about the disparity between cures seen in Eastern Europe vs. North America.

It's a good read, and you will see how much of a struggle this would have been without close FDA direction and advice on ensuring compliance with requirements.
AllGuesswork
Posts: 143
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:41.25
RE: Paratek potential take over.
Sun 20:34
Hanibal: do you not consider the speed at which iclaprim kills bacteria to be an advantage? They’ve demonstrated its more than twice as fast...

How about fixed dosing? Not important?




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.